Oxyglobin Price Essays and Term Papers

  • Biopure

    substitute Derived from bovine hemoglobin  Transports oxygen to tissue  Oxyglobin - animal (dog)  Hemopure – human   Human version more refined  Clinical trials anticipated 2 Market Summary Animal blood substitute (Oxyglobin)  Available – 5,400,000 units  15,000 clinics * 800 cases...

    Premium | 1275 Words | 9 Pages

  • Oxyglobin

    Yanping Chen Oxyglobin should be the first There were some debates of marketing strategy made the management level of Biopure very headache. Should Oxyglobin been introduced to the market earlier than Hemopure? Andy Wright , vice president for veterinary products said Yes. While Ted...

    Premium | 1770 Words | 6 Pages

  • Biopure Solution

    Course: Strategic Marketing Management Name: Firat Sekerli The Problem: Biopure Corporation has two new products that are Oxyglobin and Hemopure. Oxyglobin is the first new blood substitute for the veterinary market and is ready for consumer use. Hemopure is another new blood substitute for...

    Premium | 672 Words | 3 Pages

  • Biopure Case Study

    Biopure Corporation have two new products that are Oxyglobin and Hemopure. Oxyglobin is the first blood substitute for the veterinary market and is ready for launch. Hemopure is another new blood substitute for the human market and will take two years to launch. Ted Jacobs, VP (Human Clinical Trials)...

    Premium | 718 Words | 6 Pages

  • Corporate Finance

    biopharmaceutical company that specializes in synthesis of blood substitute for both human use and animal use. Biopure’s blood substitute for veterinary use, Oxyglobin, has received FDA approval for large scale synthesis and selling, while Biopure’s blood substitute for Human use, Hemopure, is yet to receive the...

    Premium | 1632 Words | 5 Pages

  • Biopure

    Problem – Question #6 Biopure’s main concern about an immediate launch of Oxyglobin is its possibly negative effect on the eventual pricing of Hemopure. If Biopure were to decide to launch Oxyglobin now, an appropriate marketing mix would target those market segments with the greatest need...

    Premium | 437 Words | 2 Pages

  • Biopure Case

    pharmaceuticals that are intravenously administered to deliver oxygen to the body's tissues. Biopure's two products, Hemopure for human use, and Oxyglobin for animal veterinary use, both represented a new Oxygen based treatment approach for managing patients' oxygen requirements in a broad range of potential...

    Premium | 1638 Words | 4 Pages

  • Marketing

    Biopure was grappling with the decision to launch Oxyglobin immediately versus delaying the launch after the Hemopure product was approved and established in the market. Proponents of the “launch now” view argue that the company would benefit from the Oxyglobin revenues; capital that could be used toward the...

    Premium | 794 Words | 3 Pages

  • Biopure

    market Oxyglobin, and whether to launch it concurrently or separately from Hemopure. In addition to these issues, questions exist regarding the pricing of Oxyglobin if it is launched prior to Hemopure, and what veterinarians the initial marketing strategy should focus on. How to market Oxyglobin is contingent...

    Premium | 666 Words | 2 Pages

  • Corporate Finance

    biopharmaceutical company that specializes in synthesis of blood substitute for both human use and animal use. Biopure’s blood substitute for veterinary use, Oxyglobin, has received FDA approval for large scale synthesis and selling, while Biopure’s blood substitute for Human use, Hemopure, is yet to receive the...

    Premium | 1632 Words | 5 Pages

  • Biopure Case Study Report

    Summary * Biopure Corporation developed two new products to enter into the field of blood substitutes: Hemopure, directed to the human market and Oxyglobin, for the veterinary market. Through the end of 1997 no blood substitute had received approval for use anywhere in the world. * What distinguishes...

    Premium | 2663 Words | 8 Pages

  • BIOPURE CORP.

    launch Oxyglobin and how to launch it without jeopardizing the potential of Hemopure. Oxyglobin is a substitute to animal blood while Hemopure is a substitute to human blood. The CEO need to identify the influence of the launch of Oxyglobin bring to Hemopure. If the company is launching Oxyglobin, the...

    Premium | 640 Words | 2 Pages

  • Biopure Case

    of whether it should release one of its products or not. The product is named Oxyglobin, and it is designed as a blood substitute for small animals. The key issue here is whether to release or not; and if release, what price to charge and how to distribute. After research and analyze carefully about the...

    Premium | 2040 Words | 6 Pages

  • Biopure Case

    immediately launch Oxyglobin rather than wait for Hemopure's FDA Approval then launch both products simultaneously. The proposed price for Oxyglobin is $300 per unit with promotion campaign from time to time. With this set price of immediate launch, Biopure will reach breakeven point for Oxyglobin in year 2000...

    Premium | 7016 Words | 20 Pages

  • Case Study 1 Biopure Case Questions

    each segment at the suggested prices ($600-$800) As the case said the Biopure in human market, sometime the Hemopure could be $600-$800 per unit, which is very higher price than the Oxyglobin. This high price product which relevant market segments should be taken this price level , following the attach...

    Premium | 1807 Words | 7 Pages

  • Biopure notes

    Potential – 1,749,375 units a. Set price at $100, lower prices would result in a loss to Biopure b. Percentage of Vets willing to use * Percentage of Owners willing to use * number of dogs that would benefit * 1.5 units per dog 3. Target – 249,750 units a. Set price at $200 i. Maximize profit ii....

    Premium | 1103 Words | 6 Pages

  • Biopure

     Brief Overview: Biopure has two new products namely Oxyglobin and Hemopure. Oxyglobin is a first of its kind, new blood substitute for the veterinary market and has passed all the tests and is ready for consumer use. Hemopure is another such blood substitute for the human market and it will take...

    Premium | 1060 Words | 6 Pages

  • Biopure Case Study

    key issue is to determine when Oxyglobin should be introduced to the market without jeopardizing Hemopure’s potential and how it should be marketed. In addressing the issue, the following were considered: a sensitivity analysis for potential consumption of different price series, associated revenues...

    Premium | 935 Words | 3 Pages

  • Biopure’s Case Study

    market is the pricing for Oxyglobin. It is the dilemma to price Oxglobin. If the price is too high, pet owners will not accept to use Oxglobin to treat the pet. Moreover, vets tend to use simple and cheaper way to treat pet if Oxglobin is priced to high. However, if Oxglobin price is low, vets may not consider...

    Premium | 804 Words | 3 Pages

  • Oxypure

    respect to P, we get the optimal price as Popt = (you can calculate it) And the optimal gross profit for the case where Biopure were to ... Biopure ... this case, it is important to note that the human market already has two competitors who are planning to price between $600 and $800, therefore,...

    Premium | 553 Words | 3 Pages